• In early August 2026, Halozyme Therapeutics reported record second-quarter results, with revenue rising to US$481 million and net income reaching US$229.91 million, alongside higher full-year 2026 revenue guidance of US$1.84 billion to US$1.91 billion.
• The company also accelerated shareholder returns by completing two buyback tranches totaling 4,800,000 shares for about US$332.64 million, while signing multiple new ENHANZE collaborations that broaden its royalty base and technology footprint.
• We'll now examine how Halozyme's raised 2026 revenue guidance and accelerating royalty growth reshape the investment narrative built around its ENHANZE platform.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE can remain a preferred subcutaneous delivery platform while royalty streams from a concentrated partner base stay resilient. The latest record quarter and higher 2026 revenue guidance support that royalty-led story in the near term, but they do not eliminate key risks around partner concentration, reimbursement pressure, or ongoing intellectual property challenges, which still look like the main swing factors for the stock right now.

Among the recent updates, the acceleration of share repurchases stands out alongside the earnings beat. Halozyme completed two buyback tranches totaling 4,800,000 shares for about US$332.64 million under existing authorizations. For investors focused on near-term catalysts, these buybacks matter because they amplify the impact of rising royalty income and higher 2026 guidance per share, while the core risk around ENHANZE’s reliance on a handful of blockbuster partners remains firmly in the background.

Yet behind the strong quarter, investors should be aware of how exposed Halozyme still is to shifts in partner performance and future drug pricing reforms...

Halozyme Therapeutics' narrative projects $2.1 billion revenue and $1.1 billion earnings by 2029.

Uncover how Halozyme Therapeutics' forecasts yield a $86.89 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to reach about US$2.3 billion and earnings around US$1.2 billion by 2029, but after this guidance raise and royalty acceleration, you can see how their upbeat view on ENHANZE dependence and legal outcomes sits in sharp contrast to more cautious takes that focus on partner concentration and policy risk, reminding you that reasonable investors can look at the same numbers and reach very different conclusions.

Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.